Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Triamcinolone with UVB and Dithranol for Psoriasis (DIPSO)
NCT01429870Phase 4Withdrawn
- Sponsor
- University of Zurich
- Start
- Aug 2011
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone acetonide in psoriasis (2 arms), sponsored by University of Zurich. Primary endpoints: Time to Relapse at 2 years and Time to PASI 75 at 2 years. Planned start Aug 2011; status: withdrawn.
02
Drugs
triamcinolone acetonide
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT01429870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429870.